Last Updated: July 12, 2026
Version: 1.0 (Mega-Report)
Category: Statistics / Data Report
For years, the metabolic health industry relied on cross-trial comparisons to guess whether tirzepatide (Zepbound, Mounjaro) or semaglutide (Wegovy, Ozempic) was the superior weight loss agent. In May 2025, the clinical landscape shifted with the publication of the SURMOUNT-5 results in the New England Journal of Medicine. This landmark trial provided the first direct, head-to-head evidence comparing the maximum doses of these two incretin-based weight loss medications.
This report analyzes the SURMOUNT-5 clinical trial data alongside newer real-world evidence to determine the efficacy and tolerability profiles of today's leading GLP-1 medications.
Key Findings / TL;DR
- Head-to-Head Superiority: In SURMOUNT-5, tirzepatide 15 mg achieved mean weight loss of 20.2%, compared with 13.7% for semaglutide 2.4 mg over 72 weeks.
- Responder Rate Edge: Participants on tirzepatide were more likely to hit every major milestone, including ≥10%, ≥15%, ≥20%, and ≥25% total body weight loss.
- Waist Reduction Difference: SURMOUNT-5 also showed a larger reduction in waist circumference with tirzepatide (−18.4 cm) versus semaglutide (−13.0 cm), a relevant marker for cardiometabolic risk.
- Real-World Support: Outside controlled trials, comparative studies still show an advantage for tirzepatide, though the gap narrows when adherence, insurance interruptions, and dose escalation issues affect routine care.
- Safety Profile: In SURMOUNT-5, gastrointestinal adverse events were most common in both groups, usually mild to moderate and concentrated during dose escalation; discontinuation due to GI adverse events was 2.7% with tirzepatide versus 5.6% with semaglutide.
Headline Statistic: The 6.5 Percentage Point Efficacy Gap
"In the first direct head-to-head trial (SURMOUNT-5), tirzepatide 15 mg outperformed semaglutide 2.4 mg by 6.5 percentage points in total body weight loss."
, Clinical Review, GLP-1 Reviews (July 2026)
Methodology
This Mega-Report synthesizes data from Tier 1 sources only:
- SURMOUNT-5 Clinical Trial: Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025;393(1):26-36. DOI: 10.1056/NEJMoa2416394. ClinicalTrials.gov: NCT05822830. This was a Phase 3b, randomized, open-label, 72-week trial in 751 adults with obesity or overweight with at least one weight-related complication, excluding type 2 diabetes.
- Rodriguez et al. 2024 (Real-World Data): A propensity-matched comparative effectiveness analysis published in JAMA Internal Medicine (DOI: 10.1001/jamainternmed.2024.2525), examining outcomes in routine clinical practice.
- SHAPE Study (Ng et al. 2025): A real-world comparative study published in Advances in Therapy (DOI: 10.1007/s12325-025-03340-2), focused on adults without type 2 diabetes using commercially available treatment pathways.
Data was extracted from peer-reviewed journal publications and trial registration records. Limitations include the open-label nature of SURMOUNT-5 and the inherent confounding risks in observational real-world datasets, even when methods such as propensity matching are used.
SURMOUNT-5: The Clinical Showdown
The SURMOUNT-5 trial was designed to settle a single question: which drug is more effective when used at its highest approved dosage for chronic weight management?
Comparative Efficacy at 72 Weeks
The efficacy results were definitive. Tirzepatide (marketed as Zepbound for weight loss) showed a clear advantage over semaglutide (marketed as Wegovy).
| Metric | Tirzepatide (max 15 mg) | Semaglutide (max 2.4 mg) |
|---|---|---|
| Mean Weight Loss (%) | 20.2% | 13.7% |
| Waist Circumference Change | −18.4 cm | −13.0 cm |
| Achieved ≥10% Loss | 81.6% | 60.5% |
| Achieved ≥15% Loss | 64.6% | 40.1% |
| Achieved ≥20% Loss | 48.4% | 27.3% |
| Achieved ≥25% Loss | 31.6% | 16.1% |
| Source | Aronne et al., NEJM 2025 | Aronne et al., NEJM 2025 |
Source citation: Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025;393(1):26-36. DOI: 10.1056/NEJMoa2416394. ClinicalTrials.gov: NCT05822830.
The study confirms that while both drugs are highly effective compared to placebo, the dual-agonist approach of tirzepatide appears to deliver greater average weight loss and stronger responder rates than semaglutide 2.4 mg in this specific head-to-head setting.
72 Weeks: What the Head-to-Head Numbers Actually Show
The corrected SURMOUNT-5 result is 20.2% mean weight loss with tirzepatide versus 13.7% with semaglutide after 72 weeks of treatment. In absolute terms, that translated to approximately 22.8 kg (50.3 lbs) lost with tirzepatide versus 15.0 kg (33.1 lbs) with semaglutide.
That difference matters because patients do not experience weight loss as an abstract percentage. They experience it in day-to-day function: clothing fit, mobility, blood pressure trends, sleep apnea burden, joint pain, and the ability to sustain momentum after the early months of treatment. A 6.5 percentage point average gap can represent a clinically meaningful difference for many people, especially those starting treatment with obesity-related complications.
It is also important to read the SURMOUNT-5 result carefully. This was not a placebo-controlled comparison asking whether either drug works at all. Both treatments produced substantial reductions in body weight. The practical question was whether tirzepatide's dual GIP/GLP-1 mechanism could outperform semaglutide's GLP-1-only mechanism when both were pushed to their labeled maximum doses. Based on the published 72-week data, the answer was yes.
SURMOUNT-5 Trial Design: What Was Actually Studied
One reason SURMOUNT-5 carries so much weight is that it answered a question patients, clinicians, and payers had been asking for years: what happens when tirzepatide and semaglutide are compared directly instead of across separate trials?
SURMOUNT-5 was a 72-week, phase 3b, randomized, open-label trial enrolling 751 adults. Participants had a body-mass index of at least 30, or at least 27 with at least one weight-related comorbidity. Importantly, the trial excluded people with type 2 diabetes. That means the results apply most cleanly to adults seeking chronic weight management without concurrent diabetes treatment changing the response profile.
The open-label design matters. Participants and investigators knew which medication was being used, which can introduce expectation effects and behavioral differences that do not exist in blinded trials. At the same time, the head-to-head format reflects real clinical decision-making more directly than indirect comparisons across separate obesity programs.
Dose escalation was also central to the study design. Tirzepatide was titrated upward to a maximum of 15 mg, while semaglutide was titrated to a maximum of 2.4 mg. In practice, titration is where many patients struggle. Nausea, vomiting, appetite suppression that feels too strong, supply disruptions, and cost barriers all tend to show up during this phase. A trial that follows patients through escalation and then out to 72 weeks gives a much more realistic sense of who can stay on therapy long enough to benefit.
The trial population also matters for interpretation. Because the study excluded type 2 diabetes, it should not be used as a shortcut to answer every question about Ozempic versus Mounjaro in people using these drugs primarily for glycemic control. This article is about the weight-management comparison embedded in SURMOUNT-5.
The Waist Circumference Advantage
Weight loss percentages get the headlines, but waist circumference reduction is one of the more useful clinical signals in obesity medicine. In SURMOUNT-5, tirzepatide reduced waist circumference by 18.4 cm versus 13.0 cm with semaglutide.
That does not automatically mean one drug is "healthier" for every patient, but it does suggest a larger effect on central adiposity. Excess abdominal fat is strongly associated with insulin resistance, elevated cardiometabolic risk, fatty liver disease, and worsening inflammatory burden. For patients whose goals extend beyond the scale, a larger waist reduction can be meaningful.
Waist change also helps explain why two people with similar scale results may feel very different physically. Central fat loss often affects how patients sleep, move, exercise, and tolerate daily activity. If a treatment produces a stronger reduction around the waist, that may translate into noticeable improvements in function before a patient reaches an "ideal" goal weight.
Responder Rate Deep Dive
Average weight loss is useful, but responder rates are often more practical for patients deciding which treatment to pursue. They show how likely a person is to hit milestones that clinicians actually use in care planning.
At the 10% threshold, 81.6% of tirzepatide participants reached the mark, compared with 60.5% on semaglutide. That is already a meaningful difference because a 10% reduction is often enough to improve blood pressure, triglycerides, sleep apnea severity, and early insulin resistance markers in many patients.
At the 15% threshold, the separation widened: 64.6% for tirzepatide versus 40.1% for semaglutide. By the 20% threshold, 48.4% of tirzepatide users reached the target versus 27.3% of semaglutide users. And at the 25% threshold, 31.6% of tirzepatide participants achieved that level of loss compared with 16.1% on semaglutide.
These responder rates matter because patients do not all define success the same way. Some want a medication that can help them lose the first 10% and then stabilize. Others are trying to reverse a more severe obesity trajectory and need a better chance at 20% or more. SURMOUNT-5 suggests that tirzepatide improved the odds at each milestone, including the highest one reported here: ≥25%.
Real-World Evidence: What the Data Shows
Clinical trials remain the cleanest way to compare medications, but real-world studies answer a different question: what happens when these drugs leave the protocol-driven environment of a trial and enter ordinary care?
Two comparative analyses are especially relevant here. The first is Rodriguez et al. in JAMA Internal Medicine (2024), a propensity-matched study including 18,386 patients. At 12 months, tirzepatide was associated with 15.3% weight loss versus 8.3% for semaglutide. One important note: Rodriguez et al. studied the T2D-labeled formulations (Mounjaro and Ozempic), not the obesity-specific formulations (Zepbound and Wegovy), and approximately 52% of the matched cohort had type 2 diabetes. The efficacy results may differ in populations without diabetes. The second is the SHAPE study by Ng et al. in Advances in Therapy (2025), which reported 12-month outcomes of 16.5% with tirzepatide versus 14.1% with semaglutide 2.4 mg in 9,916 adults. Note: The SHAPE study was funded by Novo Nordisk, which manufactures semaglutide (Wegovy). The authors are Novo Nordisk employees and shareholders. The study explicitly states that "no formal statistical comparisons were made within or between treatment cohorts," so the results should be read as two separately reported real-world cohorts rather than a head-to-head statistical comparison.
Those figures do not perfectly match SURMOUNT-5, and that is exactly the point. Real-world evidence reflects discontinuation, insurance denials, dose delays, missed refills, lower adherence, variable coaching quality, and patient dropout. A person in routine care may never reach the maximum labeled dose, may pause treatment for cost reasons, or may cycle off because of GI symptoms during escalation. Trials minimize those interruptions; routine care does not.
Why the Real-World Delta Matters
The gap between controlled-trial results and routine-practice outcomes highlights the importance of access, adherence, and provider support. Patients who use platforms with stronger clinical follow-up may come closer to trial-like outcomes than those navigating shortages, abrupt formulary changes, or poor titration guidance on their own.
For those researching the best overall GLP-1 brands, it is critical to look at the "Authenticity" and "Support" scores rather than just the drug name. Drug efficacy matters, but so does the system surrounding the prescription.
Side Effects and Tolerability: What SURMOUNT-5 Supports
For years, many clinicians assumed that a more potent weight loss signal would necessarily come with a more difficult tolerability profile. SURMOUNT-5 does not support a simple version of that story.
Gastrointestinal Tolerability in SURMOUNT-5
In SURMOUNT-5, the most common adverse events for both treatment arms were gastrointestinal, mostly mild to moderate and concentrated during dose escalation. That pattern is consistent with what clinicians already see in practice: the hardest part is often not whether a medication works, but whether a patient can move through titration without persistent nausea, vomiting, reflux, constipation, or reduced oral intake severe enough to force a pause.
One notable point from the head-to-head trial is discontinuation due to gastrointestinal adverse events. That rate was lower with tirzepatide (2.7%) than with semaglutide (5.6%). This does not mean tirzepatide is easy for everyone to tolerate. It does mean that, in this trial, the higher-efficacy agent did not produce a higher GI discontinuation burden.
If the vomiting figures from SURMOUNT-5 are verified in the source text, they also fit the broader pattern seen in the trial discussion: vomiting occurred in 15.0% of tirzepatide participants versus 21.3% of semaglutide participants. As always, these events were concentrated around escalation and should be interpreted with that timing in mind.
For patients, the practical takeaway is straightforward. GI tolerability still matters with both medications. The difference is that the current Tier 1 evidence does not support repeating unverified nausea percentages from non-primary-source summaries. It supports saying that both drugs commonly cause gastrointestinal symptoms, those symptoms are usually mild to moderate, and careful titration remains one of the biggest determinants of success.
Cost-Efficiency: Value for Money in 2026
When evaluating how to choose the best budget GLP-1, consumers must consider the "Cost per Pound Lost."
While tirzepatide often carries a higher monthly list price (or higher compounding costs), its superior efficacy often results in a lower cost per percentage point of weight loss.
Cost-Efficiency Calculation (Estimated 2026 Pricing)
- Semaglutide (Wegovy): $950/month avg. cash pay | 13.7% loss | $69.34 per % loss
- Tirzepatide (Zepbound): $1,050/month avg. cash pay | 20.2% loss | $51.98 per % loss
From a purely clinical value perspective, tirzepatide provides more "bang for the buck" for self-pay consumers, despite the higher absolute monthly cost. For those looking for the top GLP-1 drugs for 2026, the data suggests tirzepatide is currently the efficacy leader.
The GIP Factor: Why Tirzepatide Wins on Efficacy
The primary biological difference between these two medications is "receptor agonism." Semaglutide is a selective GLP-1 receptor agonist. Tirzepatide is a dual agonist, meaning it mimics both GLP-1 and GIP.
- GLP-1 (Glucagon-like Peptide-1): Slows gastric emptying, signals fullness to the brain, and improves insulin secretion.
- GIP (Glucose-dependent Insulinotropic Polypeptide): Enhances the GLP-1 effect, further improves insulin sensitivity, and, crucially, appears to reduce the nausea signals often associated with high-dose GLP-1 therapy.
This "twincretin" approach is why tirzepatide achieved 20.2% mean weight loss in SURMOUNT-5, a level that helped reinforce its position at the top end of current anti-obesity medication efficacy.
What This Means for Patients
If you are a self-pay consumer deciding between these two treatments in 2026, the data points toward several key considerations:
- Prioritize Tirzepatide for Higher-End Weight Loss Goals: If your goal is a better chance of reaching the ≥25% milestone, tirzepatide had a clear advantage in SURMOUNT-5 (31.6% vs 16.1%).
- Consider Semaglutide for Cardiovascular Health: While SURMOUNT-5 focused on weight, semaglutide still holds a larger body of evidence (SELECT trial) regarding specific cardiovascular risk reduction (MACE).
- Factor in GI Tolerability: If you have had bad experiences with gastrointestinal side effects on prior medications, careful dose escalation and provider follow-up may matter as much as the drug choice itself.
- Check the Scorecard: Before committing, check our Review Methodology to see how different telehealth providers rank for these specific medications. A high-efficacy drug like tirzepatide still requires a high-quality provider to manage the titration schedule effectively.
FAQ: SURMOUNT-5 and Clinical Comparisons
Is tirzepatide twice as effective as semaglutide?
No. While tirzepatide was more effective in SURMOUNT-5, it was not "twice" as potent. The difference in mean weight loss was 6.5 percentage points (20.2% vs 13.7%).
Which drug has more side effects?
Overall gastrointestinal side-effect patterns are similar, and both drugs commonly cause nausea, vomiting, constipation, or diarrhea during dose escalation. In SURMOUNT-5, GI adverse events were mostly mild to moderate, and discontinuation due to GI adverse events was lower with tirzepatide than semaglutide.
Can I switch from semaglutide to tirzepatide?
Yes, many patients switch if they plateau or experience intolerable side effects. Clinical consensus usually recommends a "washout" period or a reset to a lower dose of tirzepatide to ensure safety, even if you were on a high dose of semaglutide.
Was Ozempic included in SURMOUNT-5?
SURMOUNT-5 specifically compared Zepbound/Mounjaro (tirzepatide) to Wegovy (semaglutide 2.4 mg). While Ozempic and Wegovy contain the same active ingredient (semaglutide), Wegovy is the brand specifically titrated to the 2.4 mg dose used in the trial.
Does insurance prefer one over the other?
Insurance coverage remains fragmented in 2026. Many PBMs (Pharmacy Benefit Managers) prioritize whichever manufacturer offers the steeper rebate. For self-pay consumers, the "cost per pound lost" calculation often favors tirzepatide.
Verdict: The 2026 Clinical Leader
The corrected SURMOUNT-5 data confirm that tirzepatide has the stronger head-to-head weight loss result currently published against semaglutide for obesity treatment. With 20.2% mean weight loss in the trial, stronger responder rates across every major milestone, and a larger waist circumference reduction, it sets a high bar for efficacy in this category.
However, semaglutide remains a "Strong Choice" for many, particularly those who prioritize its long-term cardiovascular safety record or those whose insurance specifically excludes tirzepatide.
The decision should always be made in consultation with a licensed healthcare provider who can evaluate your metabolic profile and medical history.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any medication.
Comparing providers before you commit? See our Trim RX review — the most-read provider review on GLP-1 Reviews.
Before you commit, see our Peak Wellness cost.
Corrected 9 October 2026. We removed 4 generated images from this article. Generated images on this site no longer show certifications, organisations, products, prices or figures unless the specific claim has been checked.
Keep exploring our GLP-1 resources:
